Rubius Therapeutics Stock Performance
Rubius Therapeutics stock opened at $0.93 on Tuesday. The firm has a market capitalization of $83.76 million, a P/E ratio of -0.42 and a beta of 2.54. The stock has a fifty day moving average price of $0.81 and a 200 day moving average price of $1.96. Rubius Therapeutics has a 52 week low of $0.65 and a 52 week high of $20.99. The company has a current ratio of 4.63, a quick ratio of 4.63 and a debt-to-equity ratio of 0.80.
Hedge Funds Weigh In On Rubius Therapeutics
Several institutional investors have recently added to or reduced their stakes in RUBY. Renaissance Technologies LLC increased its stake in Rubius Therapeutics by 617.0% in the second quarter. Renaissance Technologies LLC now owns 826,458 shares of the company’s stock valued at $703,000 after purchasing an additional 711,190 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Rubius Therapeutics by 28.9% in the fourth quarter. JPMorgan Chase & Co. now owns 3,161,516 shares of the company’s stock valued at $30,602,000 after purchasing an additional 708,647 shares during the last quarter. Victory Capital Management Inc. grew its position in Rubius Therapeutics by 20.0% during the first quarter. Victory Capital Management Inc. now owns 2,932,248 shares of the company’s stock valued at $16,157,000 after acquiring an additional 489,248 shares during the period. ARCH Venture Management LLC purchased a new stake in Rubius Therapeutics during the fourth quarter valued at about $3,387,000. Finally, State of Michigan Retirement System grew its position in Rubius Therapeutics by 88.2% during the first quarter. State of Michigan Retirement System now owns 640,000 shares of the company’s stock valued at $3,526,000 after acquiring an additional 300,000 shares during the period. 86.84% of the stock is currently owned by institutional investors and hedge funds.
About Rubius Therapeutics
Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
- Get a free copy of the StockNews.com research report on Rubius Therapeutics (RUBY)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.